Researchers in the United States have reported a landmark development in the treatment of type 1 diabetes, after successfully implanting genetically modified pancreatic cells that produced insulin for several months without the need for immunosuppressive drugs. The early-stage study raises cautious optimism about a future therapy capable of addressing the autoimmune nature of the disease rather than managing its symptoms alone.
The experimental procedure was conducted by Sana Biotechnology, a biotechnology company based in Seattle, United States. Scientists transplanted pancreatic islet cells derived from a deceased donor into an individual with type 1 diabetes. Using CRISPR gene-editing technology, the cells were altered to evade immune detection, enabling insulin production without triggering the immune attack that typically destroys beta cells in people with the condition.
Type 1 diabetes is an autoimmune disorder that affects millions worldwide and requires lifelong insulin therapy to regulate blood glucose levels. Traditional islet transplantation from deceased donors can eliminate the need for insulin injections for extended periods, but its use remains limited due to organ shortages and the requirement for continuous immunosuppressive medication, which increases the risk of infections and cancer.
The new approach aims to overcome these limitations by modifying stem-cell-derived beta cells so they are effectively “invisible” to the immune system. According to experts involved in the research, the strategy builds on earlier attempts using unmodified cells, which showed promise but depended on long-term immunosuppression.
In this initial trial, only one participant received a relatively low dose of approximately 80 million edited cells, a number chosen primarily for safety. Despite the limited scale, the transplanted cells secreted insulin for at least 12 weeks, with follow-up reports indicating continued function for up to six months. Importantly, only cells carrying all the intended genetic modifications survived, suggesting that immune evasion was central to their persistence.
Specialists have urged caution in interpreting the findings. Tim Kieffer, a molecular endocrinologist at the University of British Columbia in Canada, noted that clinical effectiveness has not yet been established. Nonetheless, he described the concept of shielding transplanted cells from immune recognition as a potentially transformative step towards cell-based therapies that do not rely on chronic immunosuppression.
Other research programmes in the United States and abroad are pursuing related strategies. Vertex Pharmaceuticals, for example, has developed pancreatic islets from embryonic stem cells and implanted them in patients with type 1 diabetes, with several participants discontinuing insulin use after one year. However, this approach still requires immunosuppressive drugs. In China, Reprogenix is producing insulin-secreting cells by reprogramming patients’ own adipose tissue, though immune suppression remains necessary.
Sana’s method differs by combining gene inactivation to prevent recognition by T cells with the introduction of CD47, a protein that protects cells from destruction by natural killer cells. While this dual strategy has drawn interest, some immunologists have questioned the reliability of CD47-based immune protection, citing difficulties in reproducing similar results in other laboratories.
In an editorial published in the New England Journal of Medicine, Kevan Herold, an immunologist at Yale University in the United States, described the findings as an important first step towards a long-held goal in diabetes care: restoring natural insulin production without injections or immune-suppressing medication. He suggested that integrating protective gene editing with stem-cell-derived beta cells may offer the most promising pathway forward.
Looking ahead, both Sana Biotechnology and Vertex plan to launch larger clinical trials in the coming year to assess safety, durability and real-world effectiveness. Ethical considerations also remain part of the discussion, particularly regarding the source of stem cells. Many researchers emphasise the growing preference for reprogrammed adult cells, which avoid the ethical concerns associated with embryonic stem cells.
While substantial challenges remain, the prospect of an abundant, renewable supply of immune-protected pancreatic cells represents a significant advance. If validated in larger studies, this approach could mark a turning point in the long-term management—and potential treatment—of type 1 diabetes in the United States and beyond.